panCELLa Platform

Accelerating the Development and Commercialization of Revolutionary Therapeutics

The Pluripotent Stem Cell Solution

From technology and cell line licensing, process and analytical and development services, to clinical product procurement, Pluristyx strives to be your end-to-end support partner.

Speeding the transition of your revolutionary cell therapy product from proof of concept to commercialization.

Patent protected technologies

With our enlarged portfolio of unique non-modified and genetically engineered iPSC-based technologies, we can assist you at any stage in establishing proof of concept through to commercialization.

One Cell For All

Offering an array of gene editing technologies resulting in unparalleled functional control of commercial products.

Technologies

Click on technology to learn more

FailSafe^®

A reliable safeguard against transplants becoming tumorigenic – any unwanted cells can be eliminated with a simple source of drug treatment

Our FailSafe® technology offers an ideal solution: all transplanted cells and their derivatives that are proliferating can easily be eliminated with our “kill switch” safeguard by treating the patient with a drug instead of surgery.

Learn more

Cellular Reprogramming

Proprietary footprint-free RNA reprogramming method to generate induced Pluripotent Stem Cells (iPSC)

Pluristyx’s iPSCs are produced using mRNA, engineered to increase the level of protein/transcription factor expression and facilitate the reprogramming of somatic cells into induced pluripotent stem cells. Pluristyx’s iPSC have been shown to differentiate into a wide range of cell types.

Learn more

iACT

A groundbreaking technology that enables allograft transplantation without the need for systemic immune suppression

Our groundbreaking iACT technology with immune-modulatory genes allows the acceptance of allografts without the need for systemic immune suppression. Equipping pluripotent stem cells with this technology will allow the same cell line to be used for differentiation and ultimately transplantation into any individual.

Learn more

Cryopreservation

End-to-end cryopreservation services to ensure successful patient administration on day one.

Pluristyx employs industry experts who are skilled in the science and practice of cell therapy cryopreservation and can successfully design practical and economical cryopreservation methods individualized for specific cell therapy.

Learn more

REA Process & Licensing

Try Before You Buy

By offering the Research Evaluation Agreement you can gain access to our modified and non-modified cellular products for evaluation with our Try Before You Buy model. A smaller upfront payment limits your risk. Once you see the successful results, you can then enter into a license agreement with us panCELLa / Pluristyx.

Learn more

Simplifying Stem Cell Production

Pluristyx makes the complicated pluripotent stem cell manufacturing simple by shortening the development lifecycle and removing the common barriers that block the translation of tomorrow’s cell therapies to the clinic. With full control of the upstream workflow, Pluristyx can help you select, license, genetically edit, and manufacture stem cells all under one roof.

Derivation

Gene Editing

Product

Banking

Expansion

Products

Pluristyx provides PLX human pluripotent stem cells are ready for immediate evaluation in both unmodified and genetically edited versions. iPSCs are generated from regulatory-compliant donors and can be accessed for a low upfront cost to help select an appropriate line that will generate your downstream cellular product.

iPSC

Human pluripotent stem cells (iPSC) for use in R&D activities. Inquire for GMP grade cells suitable as a starting material in clinical applications.

Custom iPSC

Pluristyx can employ our mRNA reprogramming technology to generate custom hiPSC lines based on your specific requirements. Custom hiPSCs can be further modified to include our proprietary FailSafe^® or iACT™ technologies, as well as your custom genetic edits to generate the ideal starting material for your downstream product development and clinical manufacturing.

Differentiated Cells

Pluristyx staff have decades of experience generating terminally differentiated cells using both off-the-shelf and proprietary protocols. Pluristyx welcomes the opportunity to discuss and fulfill your specific differentiation needs.

iPSC

Human pluripotent stem cells (iPSC) for use in R&D activities. Inquire for GMP grade cells suitable as a starting material in clinical applications.

Custom iPSC

Differentiated Cells

Solutions

Developing the next generation of stem cell therapies is slow, hard, and expensive. Pluristyx has the expertise needed to take on the most difficult parts of your stem cell process, including CMC support, process and analytical development services, gene editing, and cell line development, to help you convert your concept into a clinical reality.

70% reduction in development time

Proprietary technology with clear freedom to operate

Fastest path to clinic

Solutions

70% reduction in development time

Proprietary technology with clear freedom to operate

Fastest path to clinic

See how we can help accelerate the development and commercialization of revoluntionary therapeutics

First Name

Last Name

Company

Country

City

State

Area of Interest

Message